Navigation Links
GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
Date:8/14/2012

WASHINGTON, D.C. The George Washington University School of Public Health and Health Services (GW) today released a report representing consensus findings from a cross-section of stakeholders that could help transform the process used to evaluate interventions to treat obesity, a public health crisis that now affects one in three adults. The report, "Obesity Drug Outcome Measures," results from a stakeholder dialogue group convened by GW that, over a period of nine months, explored why development and approval of obesity drugs have proven so difficult.

"At a time when so many Americans suffer with obesity and are faced with limited treatment options, there has been a rising call to review the emerging science on obesity to update the framework used when evaluating obesity drugs," said Christine Ferguson, J.D., Professor in the Department of Health Policy. "The FDA, under a reauthorized Prescription Drug User Fee Act, is likely to take a wider, more comprehensive look at how drugs developed to treat obesity affect how individuals with obesity feel and function. This report may help update the risk-benefit framework."

Participants in the stakeholder group all contributed to the consensus report findings and included consumer advocates, obesity experts, researchers and clinicians. Officials from the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) participated in the dialogue process, but were not asked to endorse the final report.

The consensus report outlines a series of new approaches that should be considered by the FDA when evaluating the benefits and risks of obesity drugs including:

  • Obesity affects everyone differently. Evaluating the benefits and risks of interventions should reflect the various considerations within the different categories of obesity based on feeling, functioning and health impairments.
  • Obesity drugs may provide an additional option for helping individuals who do not respond, or inadequately respond, to other interventions.
  • Potential pharmaceutical interventions should be reviewed as obesity treatments rather than weight loss agents and should be limited to only those for whom they are medically appropriate.
  • The benefit-risk evaluation of treatment with obesity drugs should extend beyond numerical weight loss to improvement in feeling and functioning.


'/>"/>
Contact: Melissa Warren
mwarren@ccapr.com
202-609-6010
Chandler Chicco Agency
Source:Eurekalert

Related medicine news :

1. Adolescents in substance abuse programs report using others med marijuana
2. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
3. Survival rates for premature babies in high-level NICUs are better than previously reported
4. New report describes 7 essential steps toward an AIDS-free generation
5. Cost Keeps Many Americans From Good Dental Care: Report
6. Inactivity May Kill as Many Worldwide as Smoking: Report
7. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
8. Reducing Ozone Limits Would Save Lives, Report States
9. Reporting of hospital infection rates and burden of C. difficile
10. Report focuses on sustainability of infectious disease surveillance
11. 20% of U.S. Women Uninsured in 2010, Up From 15% in 2000: Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... The Semper Fi Fund, one of the nation’s highest-rated veteran ... of videos and a compelling documentary that provide unique insights and powerful advice to ... of its ongoing mission. , Each of the videos focuses on a specific issue ...
(Date:9/19/2017)... Delaware (PRWEB) , ... September 19, 2017 , ... Driving ... and Safety Training Company by Training Industry Inc. as part of its mission to ... , Selection to the first annual 2017 Top 20 Health and Safety Training ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard sets out the ... become more efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 and ... a deadline of September 2018. , As described in this white ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Colleyville, TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® ... it’s the first in the U.S. to incorporate magnesium, a critical property for ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Director of its Pflugerville- FM 685 facility. , “We are pleased to announce ... location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology: